Literature DB >> 20516217

Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells.

Jaclyn S Long1, Joanne Edwards, Carol Watson, Sian Tovey, Kirsty M Mair, Rachel Schiff, Viswanathan Natarajan, Nigel J Pyne, Susan Pyne.   

Abstract

We demonstrate here a new concept termed "oncogene tolerance" whereby human EGF receptor 2 (HER2) increases sphingosine kinase 1 (SK1) expression in estrogen receptor-positive (ER(+)) MCF-7 HER2 cells and SK1, in turn, limits HER2 expression in a negative-feedback manner. The HER2-dependent increase in SK1 expression also limits p21-activated protein kinase 1 (p65 PAK1) and extracellular signal regulated kinase 1/2 (ERK-1/2) signaling. Sphingosine 1-phosphate signaling via S1P(3) is also altered in MCF-7 HER2 cells. In this regard, S1P binding to S1P(3) induces a migratory phenotype via an SK1-dependent mechanism in ER(+) MCF-7 Neo cells, which lack HER2. This involves the S1P stimulated accumulation of phosphorylated ERK-1/2 and actin into membrane ruffles/lamellipodia and migration. In contrast, S1P failed to promote redistribution of phosphorylated ERK-1/2 and actin into membrane ruffles/lamellipodia or migration of MCF-7 HER2 cells. However, a migratory phenotype in these cells could be induced in response to S1P when SK1 expression had been knocked down with a specific siRNA or when recombinant PAK1 was ectopically overexpressed. Thus, the HER2-dependent increase in SK1 expression functions to desensitize the S1P-induced formation of a migratory phenotype. This is correlated with improved prognosis in patients who have a low HER1-3/SK1 expression ratio in their ER(+) breast cancer tumors compared to patients that have a high HER1-3/SK1 expression ratio.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516217      PMCID: PMC2916408          DOI: 10.1128/MCB.01133-09

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  45 in total

1.  ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Authors:  D Graus-Porta; R R Beerli; J M Daly; N E Hynes
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

2.  Observer variation in immunohistochemical analysis of protein expression, time for a change?

Authors:  T Kirkegaard; J Edwards; S Tovey; L M McGlynn; S N Krishna; R Mukherjee; L Tam; A F Munro; B Dunne; J M S Bartlett
Journal:  Histopathology       Date:  2006-06       Impact factor: 5.087

3.  HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta.

Authors:  Shizhen Emily Wang; Incheol Shin; Frederick Y Wu; David B Friedman; Carlos L Arteaga
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 4.  Regulation of tumor cell motility by ERK mitogen-activated protein kinases.

Authors:  Emmanuel Viala; Jacques Pouysségur
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

5.  Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells.

Authors:  E J Goetzl; H Dolezalova; Y Kong; L Zeng
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

6.  Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism.

Authors:  Andrea Huwiler; Frauke Döll; Shuyu Ren; Sabine Klawitter; Anna Greening; Isolde Römer; Svetlana Bubnova; Luise Reinsberg; Josef Pfeilschifter
Journal:  Biochim Biophys Acta       Date:  2006-03-10

7.  Bad expression predicts outcome in patients treated with tamoxifen.

Authors:  Elizabeth Cannings; Tove Kirkegaard; Sian M Tovey; Barbara Dunne; T G Cooke; John M S Bartlett
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

8.  Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells.

Authors:  M A Sells; U G Knaus; S Bagrodia; D M Ambrose; G M Bokoch; J Chernoff
Journal:  Curr Biol       Date:  1997-03-01       Impact factor: 10.834

9.  Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy.

Authors:  Li Zheng; Jia Qiang Ren; Hua Li; Zhao Lu Kong; Hong Guang Zhu
Journal:  Cell Res       Date:  2004-12       Impact factor: 25.617

10.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

Authors:  A L Schechter; M C Hung; L Vaidyanathan; R A Weinberg; T L Yang-Feng; U Francke; A Ullrich; L Coussens
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

View more
  49 in total

1.  The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells.

Authors:  Carolyn Loveridge; Francesca Tonelli; Tamara Leclercq; Keng Gat Lim; Jaclyn S Long; Evgeny Berdyshev; Rothwelle J Tate; Viswanathan Natarajan; Stuart M Pitson; Nigel J Pyne; Susan Pyne
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

Review 2.  Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration.

Authors:  Roger A Sabbadini
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 3.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

4.  (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells.

Authors:  Keng Gat Lim; Chaode Sun; Robert Bittman; Nigel J Pyne; Susan Pyne
Journal:  Cell Signal       Date:  2011-05-18       Impact factor: 4.315

5.  Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Authors:  Liang Zhang; Xiaoen Wang; Andrea J Bullock; Marcella Callea; Harleen Shah; Jiaxi Song; Kelli Moreno; Barbara Visentin; Douglas Deutschman; David C Alsop; Michael B Atkins; James W Mier; Sabina Signoretti; Manoj Bhasin; Roger A Sabbadini; Rupal S Bhatt
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

6.  An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors.

Authors:  Marcela Vettorazzi; Emilio Angelina; Santiago Lima; Tomas Gonec; Jan Otevrel; Pavlina Marvanova; Tereza Padrtova; Petr Mokry; Pavel Bobal; Lina M Acosta; Alirio Palma; Justo Cobo; Janette Bobalova; Jozef Csollei; Ivan Malik; Sergio Alvarez; Sarah Spiegel; Josef Jampilek; Ricardo D Enriz
Journal:  Eur J Med Chem       Date:  2017-08-10       Impact factor: 6.514

Review 7.  Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Authors:  Dmitri Pchejetski; Torsten Böhler; Justin Stebbing; Jonathan Waxman
Journal:  Nat Rev Urol       Date:  2011-09-13       Impact factor: 14.432

8.  Breast cancer sphingosine-1-phosphate is associated with phospho-sphingosine kinase 1 and lymphatic metastasis.

Authors:  Junko Tsuchida; Masayuki Nagahashi; Masato Nakajima; Kazuki Moro; Kumiko Tatsuda; Rajesh Ramanathan; Kazuaki Takabe; Toshifumi Wakai
Journal:  J Surg Res       Date:  2016-06-16       Impact factor: 2.192

Review 9.  Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Authors:  C Evangelisti; C Evangelisti; F Buontempo; A Lonetti; E Orsini; F Chiarini; J T Barata; S Pyne; N J Pyne; A M Martelli
Journal:  Leukemia       Date:  2016-07-27       Impact factor: 11.528

10.  Sphingosine kinase (SphK) 1 and SphK2 play equivalent roles in mediating insulin's mitogenic action.

Authors:  Lan Dai; Yanfei Qi; Jinbiao Chen; Dominik Kaczorowski; Wen Di; Wei Wang; Pu Xia
Journal:  Mol Endocrinol       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.